Results 11 to 20 of about 32,569 (155)
CD30+ lymphoproliferative disorders [PDF]
Haematologica, 2010 CD30 antigen, originally identified as a cell surface marker of the malignant Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin’s lymphoma by the use of the Ki-1 monoclonal antibody, is a transmembrane glycoprotein member of the tumor necrosis factor (TNF) receptor superfamily.[1][1] In ...
Laurence de Leval, Philippe Gaulard
doaj +3 more sources
Posttransplant Lymphoproliferative Disorders [PDF]
Advances in Hematology, 2012 Posttransplant lymphoproliferative disorders (PTLDs) are a group of diseases that range from benign polyclonal to malignant monoclonal lymphoid proliferations.
Hazem A. H. Ibrahim, Kikkeri N. Naresh
doaj +4 more sources
Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
International Journal of Immunopathology and Pharmacology, 2020 Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure.
Abeya A Lotfi +9 more
doaj +2 more sources
Acquired Angioedema Associated with Lymphoproliferative Disorders [PDF]
Case Reports in OncologyIntroduction: Acquired angioedema due to C1 esterase inhibitor deficiency (C1INH-AAE) is most associated with lymphoproliferative disorders (LPDs), particularly low-grade B-cell subtypes. The condition remains under-recognized with long diagnostic delays
Jun Yen Ng +8 more
doaj +2 more sources
Posttransplantation Lymphoproliferative Disorders [PDF]
Archives of Internal Medicine, 2003 Posttransplantation lymphoproliferative disorders include a wide spectrum of diseases ranging from hyperplastic-appearing lesions to frank non-Hodgkin lymphoma. More than 90% of these disorders are Epstein-Barr virus-associated lesions of B-cell origin that arise in the setting of pharmacologic immunosuppression after transplantation.
Andreone P +6 more
openaire +4 more sources
Biomedicines, 2021 Besides their antiviral and immunomodulatory functions, type I (α/β) and II (γ) interferons (IFNs) exhibit either beneficial or detrimental effects on tumor progression.
Brigitte Bauvois +5 more
doaj +1 more source
“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
Frontiers in Oncology, 2022 Although the 17p deletion [del(17p)] is rare in cases of treatment-naive chronic lymphocytic leukemia (CLL), its frequency is higher in refractory/relapsed CLL – particularly in patients undergoing chemo(immuno)therapy.
Florence Nguyen-Khac +2 more
doaj +1 more source
KSHV/HHV8-Associated Lymphoproliferative Disorders: Lessons Learnt from People Living with HIV
Hemato, 2021 In 1992, Kaposi sarcoma herpesvirus (KSHV/HHV8) was discovered and identified as the causative agent for Kaposi sarcoma. Subsequently, the presence of this virus has been detected in a number of lymphoproliferative disorders in people living with HIV ...
Mark Bower, Antonino Carbone
doaj +1 more source
Siriraj Medical Journal, 2022 Objective: To study histopathological and clinical features of methotrexate-associated lymphoproliferative disorders (MTX-LPD) and post-transplant lymphoproliferative disorders (PTLD).
Preeyawat Ngamdamrongkiat +4 more
doaj +1 more source
EBV-Associated Lymphoproliferative Disorders
Clinical Pediatric Hematology-Oncology, 2021 Epstein Barr virus (EBV) is associated with a wide range of human lymphoproliferative disorders (LPD) of B, T, and natural killer (NK)-cell lineage. In children, abnormal immune response to primary EBV infection can cause peculiar forms of T/NK- cell LPD
Young Hyeh Ko
doaj +1 more source